A Plethora of GLP-1 Agonists: Decisions About What to Use and When

被引：14

作者：

Samson, Susan L. ^{[1
]}

Garber, Alan J. ^{[2
,3
,4
,5
]}

机构：

[1] Baylor Coll Med, Dept Med, One Baylor Plaza,ABBR R615, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Med, One Baylor Plaza,BCM 620, Houston, TX 77030 USA

[3] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,BCM 620, Houston, TX 77030 USA

[4] Baylor Coll Med, Dept Biochem, One Baylor Plaza,BCM 620, Houston, TX 77030 USA

[5] Baylor Coll Med, Dept Mol Biol, One Baylor Plaza,BCM 620, Houston, TX 77030 USA

来源：

CURRENT DIABETES REPORTS | 2016年 / 16卷 / 12期

关键词：

Type; 2; diabetes; Weight loss; Obesity; Impaired glucose tolerance; Impaired fasting glucose; Diabetes prevention; Pre-diabetes; GLUCAGON-LIKE PEPTIDE-1; TYPE-2; DIABETES-MELLITUS; INCRETIN-BASED THERAPIES; ONCE-DAILY LIXISENATIDE; BASAL INSULIN GLARGINE; OPEN-LABEL; RECEPTOR AGONIST; CONTROLLED-TRIAL; EXENATIDE TWICE; CARDIOVASCULAR-DISEASE;

D O I：

10.1007/s11892-016-0823-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Incretin-based therapies are important addition to our armamentarium for the treatment of type 2 diabetes (T2DM). There are six Glucagon-like peptide-1 receptor agonists (GLP-1RAs) which have received regulatory approval for clinical use. The short-acting GLP-1RAs include exenatide twice daily, liraglutide once daily, and lixisenatide once daily. The approved long-acting GLP-1RAs are administered weekly and are exenatide, albiglutide, and dulaglutide. Although all of these therapies lower hemoglobin A1C (HbA1C), there also are unique features of GLP-1RAs that have been made manifest from clinical trial data with regard to weight-loss efficacy, fasting and post-prandial glucose control, cardiovascular safety and protection, and gastrointestinal and injection adverse effects. It is imperative to consider these features when tailoring the choice of a GLP-1RA to patient specific characteristics.

引用

页数：13

共 104 条

[41] Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes [J].

Gough, Stephen C. L. ;

Bode, Bruce ;

Woo, Vincent ;

Rodbard, Helena W. ;

Linjawi, Sultan ;

Poulsen, Pernille ;

Damgaard, Lars H. ;

Buse, John B. .

LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (11) :885-893

[42] Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes2016. Diabetes Care 2016;39(Suppl. 1):S52-S59 [J].

Herman, William H. ;

Kalyani, Rita R. ;

Wexler, Deborah J. ;

Matthews, David R. ;

Inzucchi, Silvio E. .

DIABETES CARE, 2016, 39 (06) :E88-E89

[43] Professional Practice Committee [J].

Herman, William H. ;

Donner, Thomas W. ;

Dudl, R. James ;

Florez, Hermes J. ;

Fradkin, Judith E. ;

Hayes, Charlotte A. ;

Kalyani, Rita Rastogi ;

Koliwad, Suneil ;

Stankaitis, Joseph A. ;

Taveira, Tracey H. ;

Wexler, Deborah J. ;

Wolfsdorf, Joseph ;

Chiang, Jane L. ;

Berg, Erika Gebel ;

McElvaine, Allison T. .

DIABETES CARE, 2016, 39 :S3-S3

[44] The Cardiovascular Safety of Diabetes Drugs - Insights from the Rosiglitazone Experience [J].

Hiatt, William R. ;

Kaul, Sanjay ;

Smith, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14) :1285-1287

[45]

Jabbour J, 2016, END SOC 98 ANN M EXP, P15

[46]

Kahn R, 2005, DIABETOLOGIA, V48, P1684, DOI 10.1007/s00125-005-1876-2

[47] Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin [J].

Kapitza, C. ;

Forst, T. ;

Coester, H. -V. ;

Poitiers, F. ;

Ruus, P. ;

Hincelin-Mery, A. .

DIABETES OBESITY & METABOLISM, 2013, 15 (07) :642-649

[48] Cardiovascular Effects of Incretin Therapy in Diabetes Care [J].

Kim, Jongoh ;

Samson, Susan L. .

METABOLIC SYNDROME AND RELATED DISORDERS, 2014, 12 (06) :303-310

[49] Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice [J].

Koehler, Jacqueline A. ;

Baggio, Laurie L. ;

Lamont, Benjamin J. ;

Ali, Safina ;

Drucker, Daniel J. .

DIABETES, 2009, 58 (09) :2148-2161

[50]

Koska Juraj, 2012, Cardiovascular & Hematological Agents in Medicinal Chemistry, V10, P295

← 1 2 3 4 5 6 7 8 9 10 →